FDA warns LXR Biotech over CGMP (manufacturing quality rules) failures for Eternal Energy supplements, making them adulterated (legally unfit as made).
What happened
FDA inspected LXR Biotech's Rochester Hills, Michigan facility from February 25 to March 12, 2025 and issued a Form FDA 483 (inspection observations). FDA found CGMP violations for Eternal Energy Grape and Tropical Punch, including missing finished-product specifications and inadequate identity specifications and testing.
What FDA found
The firm did not establish finished-product specifications for identity, purity, strength, and composition, and did not include some ingredients used in the products.
21 CFR 111.70(e)The firm's identity specifications for two ingredients did not uniquely confirm each ingredient because other substances could meet the same criteria.
21 CFR 111.70(b)(1)The firm did not ensure its identity tests were appropriate and scientifically valid; management did not know whether the supplier-provided reference standard was valid.
21 CFR 111.75(h)(1)The firm also must verify that established product specifications are met.
21 CFR 111.73 and 21 CFR 111.75
What FDA wants
FDA asks LXR Biotech to reply in writing within 15 working days with the specific steps taken to address the violations, how recurrence will be prevented, and related documentation; if corrective actions cannot be completed in that time, state the reason and the timeframe.
Who should pay attention
- dietary supplement brands using contract manufacturers
- companies sourcing energy supplement premixes
- supplement quality and regulatory teams
This is a summary. Read the original letter on fda.gov.